Verrica Pharmaceuticals, Inc. (VRCA)
4.21
+0.03
(+0.72%)
USD |
NASDAQ |
Oct 09, 13:15
Verrica Pharmaceuticals Enterprise Value : 62.42M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 62.42M |
| October 07, 2026 | 61.73M |
| October 06, 2026 | 62.93M |
| October 05, 2026 | 64.65M |
| October 02, 2026 | 65.86M |
| October 01, 2026 | 68.17M |
| September 30, 2026 | 72.98M |
| September 29, 2026 | 67.23M |
| September 28, 2026 | 69.63M |
| September 25, 2026 | 65.68M |
| September 24, 2026 | 65.51M |
| September 23, 2026 | 69.98M |
| September 22, 2026 | 71.70M |
| September 21, 2026 | 67.74M |
| September 18, 2026 | 67.06M |
| September 17, 2026 | 70.49M |
| September 16, 2026 | 68.43M |
| September 15, 2026 | 69.29M |
| September 14, 2026 | 72.73M |
| September 11, 2026 | 74.96M |
| September 10, 2026 | 75.65M |
| September 09, 2026 | 77.54M |
| September 08, 2026 | 80.97M |
| September 04, 2026 | 81.66M |
| September 03, 2026 | 82.69M |
| Date | Value |
|---|---|
| September 02, 2026 | 83.21M |
| September 01, 2026 | 80.63M |
| August 31, 2026 | 84.41M |
| August 28, 2026 | 88.36M |
| August 27, 2026 | 77.71M |
| August 26, 2026 | 74.96M |
| August 25, 2026 | 75.48M |
| August 24, 2026 | 74.27M |
| August 21, 2026 | 73.41M |
| August 20, 2026 | 74.10M |
| August 19, 2026 | 76.33M |
| August 18, 2026 | 71.01M |
| August 17, 2026 | 74.62M |
| August 14, 2026 | 75.99M |
| August 13, 2026 | 74.10M |
| August 12, 2026 | 78.05M |
| August 11, 2026 | 80.29M |
| August 10, 2026 | 78.57M |
| August 07, 2026 | 77.88M |
| August 06, 2026 | 82.69M |
| August 05, 2026 | 85.27M |
| August 04, 2026 | 83.55M |
| August 03, 2026 | 80.80M |
| July 31, 2026 | 80.29M |
| July 30, 2026 | 80.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.888B |
| Corcept Therapeutics, Inc. | 12.49B |
| Veru, Inc. | 18.15M |
| Johnson & Johnson | 645.94B |
| Eli Lilly & Co. | 1.147T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.15M |
| Revenue (Quarterly) | 5.862M |
| Total Expenses (Quarterly) | 19.02M |
| EPS Diluted (Quarterly) | -0.6174 |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | -224.4% |
| Earnings Yield | -39.74% |
| Normalized Earnings Yield | -38.74 |